The FDA approved AbbVie's new drug application for VIEKIRA XR extended-release tablets.
Here are five notes:
1. VIEKIRA XR is an extended-release co-formulation of the active ingredients in VIEKIRA PAK.
2. It is intended to treat patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis.
3. The FDA approved VIEKIRA XR based on data from seven Phase III clinical trials that included more than 2,300 patients.
4. VIEKIRA XR is taken orally with meals.
5. AbbVie is a global, research-based biopharmaceutical company founded in 2013.